NDA 211855 · Biogen
Vumerity
Diroximel Fumarate · Oral
Last checked: Nov 20, 2026Latest source record: Sep 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 29, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
12
5 Phase 3, 5 recruiting
FAERS reports
12,103
4,667 serious, 368 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 29, 2025.
VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: The mechanism by which diroximel fumarate exerts its therapeutic effect in multiple sclerosis is unknown. MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 10, 2023 Supplement 9 · Efficacy LetterLabel
- Oct 29, 2019 Original approval · Type 2 - New Active Ingredient LabelLetterReview
1 products under this application
- VUMERITY · DIROXIMEL FUMARATE 231MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diroximel" as an intervention, any sponsor and status, largest first.
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisPivotal-lookingRecruiting
University Hospital, MontpellierAcademic, hospital or other
NCT07189325 · 250 participants (planned) · Start Jun 15, 2026 · Primary completion Jun 2031
Drug: Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons); Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) · For: Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy
Sites: Montpellier, France
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)Pivotal-lookingNot yet recruiting
University Hospital, Strasbourg, FranceAcademic, hospital or other
NCT06663189 · 200 participants (planned) · Start Jan 2025 · Primary completion Jan 2027
Drug: treatment withdrawal; Usual DMT continuation · For: Relapsing-remitting Multiple Sclerosis (RRMS)
Sites: Bordeaux, France; Caen, France; Clermont-Ferrand, France · 22 sites in all
- DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIALPivotal-lookingRecruiting
University Hospital, LilleAcademic, hospital or other
NCT07275515 · 192 participants (planned) · Start May 19, 2026 · Primary completion May 2029
Drug: DRF; Placebo · For: Stroke
Sites: Lille, France
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Pivotal-lookingNot yet recruiting
BiogenBiogen (BIIB)
NCT07483632 · 185 participants (planned) · Start Nov 16, 2026 · Primary completion Jul 28, 2034
Drug: Diroximel Fumarate; Dimethyl Fumarate and 4 more · For: Relapsing Forms of Multiple Sclerosis
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04788615 · 185 participants · Start Jul 23, 2021 · Primary completion Nov 4, 2025
Drug: Ofatumumab; First line DMT · For: Multiple Sclerosis
Sites: Bayonne, France; Amiens, France; Bordeaux, France · 41 sites in all
- A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT05083923 · 136 participants · Start Nov 18, 2021 · Primary completion Sep 11, 2024
Drug: Diroximel fumarate · For: Relapsing Forms of Multiple Sclerosis
Sites: Hefei, China; Beijing, China; Fuzhou, China · 52 sites in all
- A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT05798520 · 127 participants · Start Jul 25, 2023 · Primary completion Feb 10, 2026
Drug: BIIB091; DRF and 1 more · For: Relapsing Forms of Multiple Sclerosis
Sites: Scottsdale, Arizona; Berkeley, California; Orange, California · 77 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing1,642
- multiple sclerosis1,122
- multiple sclerosis relapse998
- diarrhoea884
- product dose omission issue829
- fatigue795
- nausea760
- headache635
- pruritus603
- memory impairment581
- fall571
- abdominal discomfort532
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 25 |
| 2020 | 479 |
| 2021 | 2,041 |
| 2022 | 2,568 |
| 2023 | 2,539 |
| 2024 | 1,855 |
| 2025 | 1,638 |
| 2026 | 944 |
Recalls
1 FDA enforcement reports for this application.
Dec 9, 2020 · Class II · Terminated
Failed dissolution specifications: out-of-specification test results observed during the buffer stage dissolution testing.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vumerity (Diroximel Fumarate)
2024 spending
$190M
Beneficiaries
2,762
21,014 claims
Per beneficiary
$68,720
$72.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $16,976,972 |
| 2021 | $99,890,637 |
| 2022 | $119,582,404 |
| 2023 | $152,400,689 |
| 2024 | $189,805,009 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
Bowen JD, Stulc J, Hunter SF, et al. · Adv Ther 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.
Ridley B, Minozzi S, Gonzalez-Lorenzo M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Safety and effectiveness of diroximel fumarate in relapsing forms of multiple sclerosis: a systematic review and meta-analysis.
Sabet H, Zanaty MA, Arafa A, et al. · Neurol Sci 2025 · Systematic Review, Meta-Analysis
- Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate).
Rousseau FS, Wang L, Sprague TN, et al. · Mult Scler Relat Disord 2023 · Randomized Controlled Trial
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.